Login / Signup

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).

Shannon L PuhallaVéronique DiérasBanu K ArunBella KaufmanHans P M W WildiersHyo S HanJean-Pierre AyoubVered StearnsYuan YuanTeresa HelstenBridget Riley-GillisErin MurphyMadan G KunduMeijing WuDavid MaagChristine K RatajczakCyril Y RamathalMichael L Friedlander
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Crossover veliparib monotherapy demonstrated limited antitumor activity in patients who experienced disease progression on placebo plus carboplatin/paclitaxel. PFI appeared to affect veliparib activity. BRCA reversion mutations may promote cross-resistance and limit veliparib activity following progression on platinum.
Keyphrases
  • open label
  • phase iii
  • phase ii study
  • double blind
  • placebo controlled
  • combination therapy
  • study protocol
  • randomized controlled trial
  • young adults
  • radiation therapy
  • chemotherapy induced